27.07.2012 - Spanish drugmaker Almirall S.A.'s inhaled treatment for lung disease COPD has been approved in all EU member states, plus Iceland and Norway.
The approval by the European Commission was expected after the CHMP gave the twice-daily drug a positive opinion in May covering use as a maintenance bronchodilator treatment to relieve symptoms in patients with chronic obstructive pulmonary disease (COPD). US approval is expected in July.
Florence-based Menarini Group will have joint commercialisation rights across the majority of EU member states (excluding the UK, the Netherlands and the Nordic countries, where Almirall retains sole marketing rights for the product) as well as Russia, Turkey and other CIS countries under the brand name Bretaris Genuair, while Almirall will market the product in Europe as Eklira Genuair.
Almirall's treatment loosens the muscles around the lungs to improve airflow. COPD makes breathing difficult and is often caused by cigarette smoking, which kills between 200,000 and 300,000 people in Europe a year, Almirall said.
16.12.2014 Two consortia combined of 144 European companies, research institutes and universities have been selected for funding by the EIT in the areas of health and raw materials. Both clusters are set to acquire €1.1bn over the next seven years.
10.12.2014 When it comes to the biggest investors in Research and Development (R&D) Swiss pharma top dogs Novartis and Roche have defended their positioning among the top ten companies worldwide – according to a recently published EU study.
05.12.2014 Austrian contract research company VTU has entered into a development and commercialisation agreement with US company RCT. The partners want to combine both companies' Pichia pastoris protein production technologies under VTU's roof.
03.12.2014 Danish biotech pharma Ascendis has successfully completed a €48m Series D financing round. The funding is expected to support its late-stage clinical trials to push its lead drug into Phase III trials.
01.12.2014 In spite of innovative new medicines on the market, the UK and Germany lag behind other countries and continue to use older medicines - especially in the treatment of cancer. French and Spanish patients, on the other hand, benefit much earlier from medical innovation.
28.11.2014 The first gene therapy for a rare genetic condition — UniQure's Glybera — is on its way to the European market. But there is a hefty price tag: Chiesi, responsible for the marketing of the orphan drug, is asking for a record price of €1.1m per patient.